February 27th 2021, 5:00pm
Updates on Waldenström macroglobulinemia treatment formed by an international consensus panel were recently finalized and published in The Lancet Haematology.
February 25th 2021, 7:46pm
Break Through Cancer, a collaborative research effort between 5 top US academic cancer centers, aims to pursue solutions to some of the most difficult challenges in cancer research.
February 18th 2021, 8:00pm
Hypertension, anemia, and infection were the most common adverse events associated with mantle cell lymphoma (MCL), while hepatotoxicity, stroke, and renal failure were the costliest per patient.
February 16th 2021, 8:00pm
Tanya Siddiqi, MD, director of the chronic lymphocytic leukemia program at Toni Stephenson Lymphoma Center provides insights on what the arrival of liso-cel could mean in the treatment landscape.
February 15th 2021, 7:53pm
Older adults with acute myeloid leukemia (AML) saw increased overall and relapse-free survival, as well as preserved quality of life, following oral administration of 300-mg azacitidine.
February 15th 2021, 7:45pm
The newly approved expanded label includes data from the final analysis of the phase 3 iNNOVATE study of ibrutinib plus rituximab vs rituximab alone.
February 14th 2021, 12:15am
Using CRISPR, researchers were able to repeat the step-by-step conversion of a normal cell into a malignant one in acute myeloid leukemia (AML).
February 12th 2021, 3:56pm
Patients with mantle cell lymphoma (MCL) who discontinue acalabrutinib may have different outcomes depending on why they stopped and their eligibility for other therapies.
February 6th 2021, 4:30pm
Results from a new clinical trial suggest that discontinuation of tyrosine kinase inhibitors (TKIs) is safe, feasible and is associated with improvements in patient-related outcomes (PROs) in chronic myeloid leukemia (CML).
February 5th 2021, 9:30pm
A CAR T-cell therapy that promises fewer side effects, and possibly lower hospital costs, wins approval after lengthy delays.
